Organogenesis Good Will vs Common Stock Analysis
ORGO Stock | USD 2.75 0.02 0.73% |
Organogenesis Holdings financial indicator trend analysis is much more than just breaking down Organogenesis Holdings prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Organogenesis Holdings is a good investment. Please check the relationship between Organogenesis Holdings Good Will and its Common Stock accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.
Good Will vs Common Stock
Good Will vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Organogenesis Holdings Good Will account and Common Stock. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Organogenesis Holdings' Good Will and Common Stock is -0.05. Overlapping area represents the amount of variation of Good Will that can explain the historical movement of Common Stock in the same time period over historical financial statements of Organogenesis Holdings, assuming nothing else is changed. The correlation between historical values of Organogenesis Holdings' Good Will and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Good Will of Organogenesis Holdings are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Good Will i.e., Organogenesis Holdings' Good Will and Common Stock go up and down completely randomly.
Correlation Coefficient | -0.05 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Good Will
An intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors.Common Stock
Most indicators from Organogenesis Holdings' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Organogenesis Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.At this time, Organogenesis Holdings' Tax Provision is very stable compared to the past year. As of the 2nd of June 2024, Sales General And Administrative To Revenue is likely to grow to 0.67, while Selling General Administrative is likely to drop about 146.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 114.2M | 105.0M | 123.4M | 69.0M | Research Development | 30.7M | 39.8M | 44.4M | 46.6M |
Organogenesis Holdings fundamental ratios Correlations
Click cells to compare fundamentals
Organogenesis Holdings Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Organogenesis Holdings fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 220.7M | 294.5M | 443.3M | 449.4M | 460.0M | 292.5M | |
Other Current Liab | 5.8M | 2.1M | 2.3M | 26.4M | 30.1M | 31.6M | |
Total Current Liabilities | 59.9M | 68.2M | 82.0M | 75.0M | 80.5M | 48.2M | |
Total Stockholder Equity | 55.6M | 146.1M | 242.0M | 265.7M | 278.7M | 179.4M | |
Other Liab | 7.7M | 15.7M | 1.6M | 1.1M | 1.3M | 1.2M | |
Net Tangible Assets | 9.2M | 86.7M | 187.6M | 216.1M | 248.5M | 261.0M | |
Retained Earnings | (171.0M) | (153.1M) | (60.1M) | (45.3M) | (41.0M) | (43.0M) | |
Accounts Payable | 28.4M | 23.4M | 29.3M | 32.3M | 30.7M | 23.8M | |
Cash | 60.2M | 84.4M | 113.9M | 102.5M | 104.3M | 53.7M | |
Other Assets | 1.6M | 688K | 33.5M | 31.5M | 1.0 | 0.95 | |
Long Term Debt | 83.1M | 53.0M | 70.8M | 66.2M | 60.7M | 65.7M | |
Net Receivables | 39.4M | 56.8M | 82.5M | 89.5M | 82.0M | 52.7M | |
Common Stock Total Equity | 293.0M | 9K | 10K | 13K | 11.7K | 11.1K | |
Inventory | 22.9M | 27.8M | 25.0M | 24.8M | 28.3M | 20.8M | |
Other Current Assets | 3.0M | 4.9M | 5.0M | 5.1M | 10.5M | 11.0M | |
Other Stockholder Equity | 226.6M | 299.1M | 302.2M | 311.0M | 319.6M | 181.3M | |
Total Liab | 165.1M | 148.4M | 201.2M | 183.7M | 181.4M | 113.0M | |
Deferred Long Term Liab | 318K | 92K | 370K | 1.2M | 1.4M | 1.5M | |
Total Current Assets | 125.6M | 174.3M | 227.0M | 222.6M | 225.0M | 115.3M | |
Short Term Debt | 3.1M | 20.3M | 14.6M | 16.2M | 19.7M | 20.7M | |
Intangible Assets | 20.8M | 30.6M | 25.7M | 20.8M | 15.9M | 22.1M | |
Common Stock | 293.0M | 9K | 10K | 13K | 11.7K | 11.1K | |
Property Plant Equipment | 47.2M | 60.1M | 79.2M | 102.5M | 117.8M | 123.7M | |
Short Long Term Debt Total | 100.6M | 84.8M | 132.3M | 123.8M | 119.4M | 85.3M | |
Net Debt | 40.4M | 377K | 18.4M | 21.3M | 15.0M | 16.2M | |
Non Current Assets Total | 95.1M | 120.2M | 216.3M | 226.8M | 235.0M | 196.6M | |
Non Currrent Assets Other | 884K | 670K | 1.5M | 1.5M | 6.0M | 5.7M | |
Cash And Short Term Investments | 60.2M | 84.4M | 113.9M | 102.5M | 104.3M | 59.6M | |
Common Stock Shares Outstanding | 92.8M | 111.4M | 133.7M | 132.4M | 132.7M | 105.4M | |
Liabilities And Stockholders Equity | 220.7M | 294.5M | 443.3M | 449.4M | 460.0M | 324.6M | |
Non Current Liabilities Total | 105.2M | 80.2M | 119.2M | 108.7M | 100.9M | 71.7M | |
Capital Surpluse | 226.6M | 299.1M | 302.2M | 311.0M | 357.6M | 182.7M | |
Non Current Liabilities Other | 6.6M | 12.0M | 48.5M | 42.4M | 1.2M | 1.2M | |
Net Invested Capital | 138.7M | 215.8M | 315.5M | 336.4M | 344.9M | 273.1M | |
Net Working Capital | 65.7M | 106.1M | 145.0M | 147.6M | 144.5M | 95.9M | |
Property Plant And Equipment Net | 47.2M | 60.1M | 128.3M | 145.7M | 156.3M | 105.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.Note that the Organogenesis Holdings information on this page should be used as a complementary analysis to other Organogenesis Holdings' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Organogenesis Stock analysis
When running Organogenesis Holdings' price analysis, check to measure Organogenesis Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Organogenesis Holdings is operating at the current time. Most of Organogenesis Holdings' value examination focuses on studying past and present price action to predict the probability of Organogenesis Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Organogenesis Holdings' price. Additionally, you may evaluate how the addition of Organogenesis Holdings to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Organogenesis Holdings' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 11.307 | Earnings Share 0.04 | Revenue Per Share 3.313 | Quarterly Revenue Growth 0.022 | Return On Assets 0.0201 |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.